Conclusion Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed.
via Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer.
All Things Palliative - Article Feed 